Skip to contentUniversity of Michigan Health System - link
Department of Internal Medicine - link
INFECTIOUS DISEASES
search this site
 

About Us



Info for Patients




Referring Physicians




Our Faculty




Education & Research



HIV/AIDS Treatment Program




More News




Internal Resources




Internal Medicine Divisions

 
Dr. Kathleen Collins

Description of Research: Kathleen Collins

HIV Disease Pathogenesis

HIV establishes a chronic infection, and leads inexorably to the development of AIDS despite the acquisition of an anti-HIV immune response. My laboratory is interested in understanding the factors that allow HIV to thwart the immune system. Thus far, we have found that HIV evades the cytotoxic T lymphocyte (CTL) arm of the immune response by limiting presentation of viral antigens. This is accomplished by downmodulating MHC-I protein, which is required for immune recognition. Downmodulation of MHC-I occurs through the action of the HIV Nef protein. Work from our laboratory has indicated that the HIV Nef protein downmodulates MHC-I by physically interacting with specific amino acid sequences located in the MHC-I cytoplasmic tail. The specificity of this interaction allows Nef to selectively downmodulate MHC-I allotypes important for CTL recognition, while maintaining the expression of MHC-I allotypes that protect cells from natural killer cell recognition. Once bound, Nef allows the transport of MHC-I molecules into the Golgi apparatus, but then prevents their expression on the cell surface by recruiting a cellular adaptor protein, AP-1, which targets the complex to lysosomes for degradation. We have also learned that the effects of Nef are cell-type-specific in that Nef is much more active in T cells, a natural target for HIV infection. We have discovered that this results from the fact that The Nef-MHC-I complex recruits AP-1 much more efficiently in T cells. This observation is important because current models derived from non-T cell systems have led to the incorrect conclusion that Nef functions exclusively by accelerating MHC-I enodocytosis. Thus, our studies have uncovered a key, previously overlooked mechanism for MHC-I downmodulation and immune evasion by HIV.

In addition, we have found that HIV limits antigen expression through the action of HIV Rev. The Rev protein normally functions by allowing late gene product mRNAs to exit the nucleus. Thus, the amount of Rev activity in the cell determines the relative amount of late gene product expression, the main source of CTL antigens. We have found that naturally occurring Rev alleles vary in their activity level and that those with less activity result in infected cells that are resistant to CTL lysis. These alleles are selected early in disease when the immune system is more active. Later on in disease, more active alleles emerge once the immune system has been destroyed and selective pressure wanes. In sum, the combined effects of Nef and Rev dramatically limit antigen presentation early in HIV disease when HIV must combat a highly active anti-HIV immune response.

Recent Publications

Wonderlich ER, Williams M, Collins KL. The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu 1 subunit is necessary for nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail. J Biol Chem 283 (6): 3011-3022, 2008.

Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells - art. no. e1000131. PLOS Path 4 (8): 131-131, 2008.

Collins KL. This Bud's for Vpu. Cell Host Microbe 5 (3): 217-219, 2009.

Thammavongsa V, Schaefer M, Filzen T, Collins KL, Carrington M, Bangia N, Raghavan M. Assembly and intracellular trafficking of HLA-B*3501 and HLA-B*3503. Immunogenetics 61 (11-12): 703-716, 2009.

Carter CC, Onafuwa-Nuga A, McNamara LA, Riddell J, Bixby D, Savona MR, Collins KL. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature Med 16 (4): 446-U127, 2010.

Garcia-Perez JL, Morell M, Scheys JO, Kulpa DA, Morell S, Carter CC, Hammer GD, Collins KL, O'Shea KS, Menendez P, Moran JV. Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. Nature 466 (7307): 769-773, 2010.

Onafuwa-Nuga A, McNamara LA, Collins KL. Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people. Cell Res 20 (11): 1185-1187, 2010.

Carter CC, McNamara LA, Onafuwa-Nuga A, Shackleton M, Riddell J, Bixby D, Savona MR, Morrison SJ, Collins KL. HIV-1 Utilizes the CXCR4 Chemokine Receptor to Infect Multipotent Hematopoietic Stem and Progenitor Cells. Cell Host Microbe 9 (3): 223-234, 2011.

Leonard JA, Filzen T, Carter CC, Schaefer M, Collins KL. HIV-1 Nef Disrupts Intracellular Trafficking of Major Histocompatibility Complex Class I, CD4, CD8, and CD28 by Distinct Pathways That Share Common Elements. J Virol 85 (14): 6867-6881, 2011.

Kulpa DA, Collins KL. The emerging role of HLA-C in HIV-1 infection. Immunology 134 (2): 116-122, 2011.

Norman JM, Mashiba M, McNamara LA, Onafuwa-Nuga A, Chiari-Fort E, Shen WW, Collins KL. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nature Immunol 12 (10): 975-NIL_83, 2011.

McNamara LA, Collins KL. Hematopoietic stem/precursor cells as HIV reservoirs. Current Open HIV AIDS 6 (1): 43-48, 2011.

Wonderlich ER, Leonard JA, Kulpa DA, Leopold KE, Norman JM, Collins KL. ADP Ribosylation Factor 1 Activity Is Required To Recruit AP-1 to the Major Histocompatibility Complex Class I (MHC-I) Cytoplasmic Tail and Disrupt MHC-I Trafficking in HIV-1-Infected Primary T Cells. J Virol 85 (23): 12216-12226, 2011.

Heigele A, Schindler M, Gnanadurai CW, Leonard JA, Collins KL, Kirchhoff F. Down-Modulation of CD8 alpha beta is a Fundamental Activity of Primate Lentiviral Nef Proteins. J Virol 86 (1):36-48, 2012.


 
   
   

U-M Medical School
| Hospitals & Health Centers | U-M | TEXT-ONLY

University of Michigan Health System
1500 E. Medical Center Drive  Ann Arbor, MI 48109   734-936-4000
(c) copyright Regents of the University of Michigan
Template developed & maintained by: Public Relations & Marketing Communications
Contact UMHS

 
The University of Michigan Health System web site does not provide specific medical advice and does not endorse any medical or professional service obtained through information provided on this site or any links to this site.
Complete disclaimer and Privacy Statement

UMHS HOME

Health Topics A-Z

For Patients & Families

For Health Professionals

Search Tools & Index